This image provided by Eli Lilly shows the company’s new Alzheimer’s drug Kisunla. The Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday, July 2, 2024 for mild or early cases of ...

The firm provided updates alongside Q4 and full-year 2025 financial results, and reported $19.29 billion and $65.18 billion ...

Eli Lilly's potential Alzheimer's disease treatment failed to slow mental decline in two late-stage studies, but combined data from both trials showed promising results in patients with ...

Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its chief executive officer said in an interview. Lilly’s drug, Kisunla, launched ...

Campaigners have blasted the move as a "major disappointment”.